The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology
Open accessAbstract
Cortical iron has been shown to be elevated in Alzheimer’s disease (AD), but the impact of the directly measured iron on the clinical syndrome has not been assessed. We investigated the association between post-mortem iron levels with the clinical and pathological diagnosis of AD, its severity, and the rate of cognitive decline in the 12 years prior to death in subjects from the Memory and Aging Project (n = 209). Iron was elevated (β [SE] = 9.7 [2.6]; P = 3.0 × 10−4) in the inferior temporal cortex only in subjects who were diagnosed with clinical AD during life and had a diagnosis of AD confirmed post-mortem by standardized criteria. Although iron was weakly associated with the extent of proteinopathy in tissue with AD neuropathology, it was strongly associated with the rate of cognitive decline (e.g., global cognition: β [SE] = -0.040 [0.005], P = 1.6 × 10−14). Thus, cortical iron might act to propel cognitive deterioration upon the underlying proteinopathy of AD, possibly by inducing oxidative stress or ferroptotic cell death, or may be related to an inflammatory response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695
Self-citationNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 2×
“This study design has not previously been employed to investigate the impact of brain iron on AD, but it has on other proteinopathies [25].”
BackgroundSelf-citationIron accumulation in Alzheimer disease is a source of redox-generated free radicals
Smith, M. A., Harris, P. L. R., Sayre, L. M., & Perry, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9866 · Cited by 1,355
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336
Self-citationFrequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 1×
“Neuritic β-amyloid plaques and neurofibrillary tangles (NFTs) are the defining proteopathies of Alzheimer’s disease (AD); yet, post-mortem pathology studies [1–3], β-amyloid positron emission tomography imaging studies [4, 5], and cerebrospinal fluid (CSF) biomarker studies [6–8] have demonstrated that severe ‘AD’ pat…”
BackgroundFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Overview and Findings from the Rush Memory and Aging Project
A. Bennett, D., A. Schneider, J., S. Buchman, A., L. Barnes, L., A. Boyle, P., & S. Wilson, R. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322663 · Cited by 862
Toledo, J. B., Arnold, S. E., Raible, K., Brettschneider, J., Xie, S. X., Grossman, M., Monsell, S. E., Kukull, W. A., & Trojanowski, J. Q. (2013) · Brain · doi:10.1093/brain/awt188 · Cited by 849
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594 · cited 1×
“could cause iron elevation, since tau promotes the stabilization of the iron-exporting protein, ferroportin, by trafficking β-amyloid precursor protein (APP) to the neuronal surface [31].”
BackgroundSelf-citationIron Homeostasis and the Inflammatory Response
Wessling-Resnick, M. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104804 · Cited by 480
Microinfarct Pathology, Dementia, and Cognitive Systems
Arvanitakis, Z., Leurgans, S. E., Barnes, L. L., Bennett, D. A., & Schneider, J. A. (2011) · Stroke · doi:10.1161/strokeaha.110.595082 · Cited by 404
Self-citationWilliams, T. I., Lynn, B. C., Markesbery, W. R., & Lovell, M. A. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.004 · Cited by 392
Brain Glutathione Levels – A Novel Biomarker for Mild Cognitive Impairment and Alzheimer’s Disease
Mandal, P. K., Saharan, S., Tripathi, M., & Murari, G. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.005 · Cited by 336
Ayton, S., Faux, N. G., Bush, A. I., Initiative, A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms7760 · Cited by 327
Self-citationCSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment: A follow-up study
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 279
Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline
Ayton, S., Fazlollahi, A., Bourgeat, P., Raniga, P., Ng, A., Lim, Y. Y., Diouf, I., Farquharson, S., Fripp, J., Ames, D., et al. (2017) · Brain · doi:10.1093/brain/awx137 · Cited by 279
Self-citationCognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies
Schneider, J. A., Arvanitakis, Z., Yu, L., Boyle, P. A., Leurgans, S. E., & Bennett, D. A. (2012) · Brain · doi:10.1093/brain/aws234 · Cited by 273
Self-citationLipid peroxidation is an early event in the brain in amnestic mild cognitive impairment
Markesbery, W. R., Kryscio, R. J., Lovell, M. A., & Morrow, J. D. (2005) · Annals of Neurology · doi:10.1002/ana.20629 · Cited by 273
Reed, T., Perluigi, M., Sultana, R., Pierce, W. M., Klein, J. B., Turner, D. M., Coccia, R., Markesbery, W. R., & Butterfield, D. A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.12.007 · Cited by 257
Rowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24040 · Cited by 222
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease
Lim, Y. Y., Maruff, P., Pietrzak, R. H., Ames, D., Ellis, K. A., Harrington, K., Lautenschlager, N. T., Szoeke, C., Martins, R. N., Masters, C. L., et al. (2014) · Brain · doi:10.1093/brain/awt286 · Cited by 210
Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease
Bradley, M. A., Markesbery, W. R., & Lovell, M. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.02.016 · Cited by 193
Cerebral Microbleeds: Burden Assessment by Using Quantitative Susceptibility Mapping
Liu, T., Surapaneni, K., Lou, M., Cheng, L., Spincemaille, P., & Wang, Y. (2012) · Radiology · doi:10.1148/radiol.11110251 · Cited by 189
Self-citationColocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment
van Bergen, J. M. G., Li, X., Hua, J., Schreiner, S. J., Steininger, S. C., Quevenco, F. C., Wyss, M., Gietl, A. F., Treyer, V., Leh, S. E., et al. (2016) · Scientific Reports · doi:10.1038/srep35514 · Cited by 180
Schneider, S. A., Hardy, J., & Bhatia, K. P. (2012) · Movement Disorders · doi:10.1002/mds.23971 · Cited by 179
Cortical iron reflects severity of Alzheimer's disease
van Duijn, S., Bulk, M., van Duinen, S. G., Nabuurs, R. J. A., van Buchem, M. A., van der Weerd, L., & Natté, R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161143 · Cited by 172
Telling, N. D., Everett, J., Collingwood, J. F., Dobson, J., van der Laan, G., Gallagher, J. J., Wang, J., & Hitchcock, A. P. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.07.014 · Cited by 169
Plascencia‐Villa, G., Ponce, A., Collingwood, J. F., Arellano-Jiménez, M. J., Zhu, X., Rogers, J. T., Betancourt, I., José–Yacamán, M., & Perry, G. L. (2016) · Scientific Reports · doi:10.1038/srep24873 · Cited by 158
Zeineh, M. M., Chen, Y., Kitzler, H. H., Hammond, R., Vogel, H., & Rutt, B. K. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.022 · Cited by 151
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Schneider, S. A., Dušek, P., Hardy, J., Westenberger, A., Jankovic, J. J., & Bhatia, K. P. (2013) · Current Neuropharmacology · doi:10.2174/157015913804999469 · Cited by 149
Tao, Y., Wang, Y., Rogers, J. T., & Wang, F. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140396 · Cited by 147
Self-citationEverett, J. L., Collingwood, J. F., Tjhin, V. T., Brooks, J., Lermyte, F., Plascencia‐Villa, G., Hands-Portman, I., Dobson, J., Perry, G. L., & Telling, N. D. (2018) · Nanoscale · doi:10.1039/c7nr06794a · Cited by 130
Montine, T. J., Kaye, J. A., Montine, K. S., McFarland, L. L., Morrow, J. D., & Quinn, J. F. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0510-cfataf · Cited by 125
Elemental imbalances in the olfactory pathway in Alzheimer's disease
Samudralwar, D. L., Diprete, C. C., Ni, B. F., Ehmann, W. D., & Markesbery, W. R. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00018-w · Cited by 118
Brain membrane fluidity and lipid peroxidation in Alzheimer's disease
Hajimohammadreza, I., & Brammer, M. J. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90226-y · Cited by 101
Evidence that iron accelerates Alzheimer’s pathology: a CSF biomarker study
Ayton, S., Diouf, I., & Bush, A. I. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316551 · Cited by 87
Self-citationAyton, S., Faux, N. G., & Bush, A. I. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4406 · Cited by 80
Self-citationLi, X., Lei, P., Tuo, Q., Ayton, S., Li, Q., Moon, S., Volitakis, I., Liu, R., Masters, C. L., Finkelstein, D. I., et al. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0378-2 · Cited by 67
Self-citationThe effect of iron in MRI and transverse relaxation of amyloid‐beta plaques in Alzheimer's disease
Meadowcroft, M. D., Peters, D. G., Dewal, R. P., Connor, J. R., & Yang, Q. X. (2014) · NMR in Biomedicine · doi:10.1002/nbm.3247 · Cited by 48
Nanoscale Imaging Reveals Big Role for Iron in Alzheimer’s Disease
Ayton, S., James, S., & Bush, A. I. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.10.002 · Cited by 15
Self-citationPrice (1999) · doi:10.1002/1531-8249(199903)45:3
Cited by
Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer’s disease
Bao, W.-D., Pang, P., Zhou, X.-T., Hu, F., Xiong, W., Chen, K., Wang, J., Wang, F., Xie, D., Hu, Y.-Z., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00685-9 · Cited by 671
Ferroptosis Mechanisms Involved in Neurodegenerative Diseases
Reichert, C. O., de Freitas, F. A., Sampaio-Silva, J., Rokita-Rosa, L., Barros, P. D. L., Levy, D., & Bydlowski, S. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228765 · Cited by 422
Molecular mechanisms of ferroptosis and their involvement in brain diseases
Costa, I., Barbosa, D. J., Benfeito, S., Silva, V., Chavarria, D., Borges, F., Remião, F., & Silva, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108373 · Cited by 402
Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism
Cui, Z., Zhao, X., Amevor, F. K., Du, X., Wang, Y., Li, D., Shu, G., Tian, Y., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943321 · Cited by 377
Self-citationThe effects of plant-based diets on the body and the brain: a systematic review
Medawar, E., Huhn, S., Villringer, A., & Veronica Witte, A. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0552-0 · Cited by 343
Metadata
- Authors
- Ayton, S., Wang, Y., Diouf, I., Schneider, J. A., Brockman, J., Morris, M. C., & Bush, A. I.
- Venue
- Molecular Psychiatry
- Published
- 2019-02-18
- Volume
- 25
- Issue
- 11
- Pages
- 2932-2941
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2914888345
- Cited by
- 365
- References
- 45
- FWCI
- 23.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.